Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- Trump threatens to bomb Oman over Iran stance
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Micron rises as White House presses Apple to avoid Chinese memory chips
Goldman Sachs Reiterates Buy on Incyte (INCY)
June 22, 2018 7:30 AM EDTGoldman Sachs reiterated a Buy rating and $97.00 price target on Incyte (NASDAQ: INCY) following the company's investor event. INCY showcased its five product late-stage portfolio in development for 15 indications.
INCY continues to advance multiple clinical development programs for patients with myeloproliferative... More
